Trial Enrollment Completed for Investigational Therapy of Exocrine Pancreatic Insufficiency First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company
March S&P 500 futures (ESH23) are trending down -0.33% this morning after three major U.S. benchmark indices shook off early losses and closed higher on Friday as investors assessed the start of the U.S....
/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage specialty biopharmaceutical company developing first-in-class drugs...
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage...
BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a...
Committee members include globally renowned experts in gastrointestinal diseases, including ulcerative colitis and Crohn’s disease...
BOCA RATON, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a...
BOCA RATON, Fla., March 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...
Poster presentation to feature research involving niclosamide as a potential treatment for mild-to-moderate ulcerative proctitis and ulcerative...
BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical...